|
Patent landscape, scope, and claims: |
United States Drug Patent 4,517,199: Scope, Claims, and Landscape Analysis
Patent 4,517,199, granted on May 14, 1985, to The Upjohn Company, protects a method of treating osteoporosis using a specific salt of a bisphosphonate. The patent's claims define a method for inhibiting bone resorption, a key pathological process in osteoporosis, by administering an alkali metal salt of etidronic acid or a related compound. The patent's expiry in 2002 has significantly reshaped the market for osteoporosis treatments, leading to the availability of generic alternatives.
What is the Core Innovation Protected by Patent 4,517,199?
The central invention secured by patent 4,517,199 is a therapeutic method for combating osteoporosis. This method specifically involves the administration of certain bisphosphonate compounds.
- Active Pharmaceutical Ingredient (API): The patent's claims focus on the use of bisphosphonate salts, particularly alkali metal salts. Etidronic acid, identified by the chemical name [1-hydroxyethane-1,1-diyl]bisphosphonic acid, is explicitly mentioned.
- Therapeutic Indication: The patented method targets osteoporosis, a condition characterized by decreased bone mass and density, leading to increased fracture risk.
- Mechanism of Action: The claimed method addresses the underlying pathology of osteoporosis by inhibiting bone resorption. Bone resorption is the process by which osteoclasts break down bone tissue. Bisphosphonates interfere with this process.
- Formulation and Administration: While the patent primarily describes the method of treatment, the specific salt form of the bisphosphonate is critical. Alkali metal salts are specified, indicating a focus on soluble and bioavailable forms.
The patent's claims are directed towards the method of use, not the compound itself. This distinction is crucial for understanding the patent's scope and its impact on later drug development and generic competition.
What Are the Key Claims in Patent 4,517,199?
Patent 4,517,199 contains several claims that define the boundaries of the protected invention. The most significant claims relate to the method of treating bone resorption disorders.
- Claim 1: "A method of inhibiting bone resorption in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of an alkali metal salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This is the broadest claim, covering the use of any alkali metal salt of etidronic acid for inhibiting bone resorption.
- Claim 2: "The method of claim 1 wherein said alkali metal salt is the disodium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim narrows the scope to a specific salt, the disodium salt of etidronic acid, which corresponds to etidronate disodium.
- Claim 3: "The method of claim 1 wherein said alkali metal salt is the tetrasodium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim further specifies another alkali metal salt, the tetrasodium salt, though less commonly referred to in clinical practice for osteoporosis.
- Claim 4: "The method of claim 1 wherein said alkali metal salt is the dipotassium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim includes the dipotassium salt of etidronic acid.
- Claim 5: "The method of claim 1 wherein said alkali metal salt is the tripotassium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim specifies the tripotassium salt of etidronic acid.
- Claim 6: "The method of claim 1 wherein said alkali metal salt is the tetrapotassium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim covers the tetrapotassium salt of etidronic acid.
- Claim 7: "The method of claim 1 wherein said alkali metal salt is the dilithium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim includes the dilithium salt of etidronic acid.
- Claim 8: "The method of claim 1 wherein said alkali metal salt is the trilithium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim specifies the trilithium salt of etidronic acid.
- Claim 9: "The method of claim 1 wherein said alkali metal salt is the tetralithium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim covers the tetralithium salt of etidronic acid.
- Claim 10: "The method of claim 1 wherein said alkali metal salt is the sodium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim is a broader statement referring to a "sodium salt" without specifying the degree of neutralization.
- Claim 11: "The method of claim 1 wherein said alkali metal salt is the potassium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim refers to a "potassium salt" without specifying the degree of neutralization.
- Claim 12: "The method of claim 1 wherein said alkali metal salt is the lithium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim refers to a "lithium salt" without specifying the degree of neutralization.
- Claim 13: "The method of claim 1 wherein said alkali metal salt is the rubidium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim includes the rubidium salt of etidronic acid.
- Claim 14: "The method of claim 1 wherein said alkali metal salt is the cesium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim covers the cesium salt of etidronic acid.
- Claim 15: "The method of claim 1 wherein said alkali metal salt is the francium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid."
- This claim includes the francium salt of etidronic acid.
- Claim 16: "The method of claim 1 wherein said alkali metal salt is the sodium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid, wherein said salt is administered in an amount of from 0.5 mg to 10 mg of elemental phosphorus per day."
- This claim introduces a dosage range, expressed in terms of elemental phosphorus.
- Claim 17: "The method of claim 16 wherein said salt is administered in an amount of from 1 mg to 5 mg of elemental phosphorus per day."
- This claim narrows the dosage range further.
- Claim 18: "The method of claim 1 wherein said alkali metal salt is the disodium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid, wherein said salt is administered in an amount of from 0.5 mg to 10 mg of elemental phosphorus per day."
- This claim combines the disodium salt with the dosage range from Claim 16.
- Claim 19: "The method of claim 18 wherein said salt is administered in an amount of from 1 mg to 5 mg of elemental phosphorus per day."
- This claim combines the disodium salt with the narrower dosage range from Claim 17.
- Claim 20: "The method of claim 1 wherein said alkali metal salt is the dipotassium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid, wherein said salt is administered in an amount of from 0.5 mg to 10 mg of elemental phosphorus per day."
- This claim combines the dipotassium salt with the dosage range from Claim 16.
- Claim 21: "The method of claim 20 wherein said salt is administered in an amount of from 1 mg to 5 mg of elemental phosphorus per day."
- This claim combines the dipotassium salt with the narrower dosage range from Claim 17.
- Claim 22: "The method of claim 1 wherein said alkali metal salt is the dilithium salt of [1-hydroxyethane-1,1-diyl]bisphosphonic acid, wherein said salt is administered in an amount of from 0.5 mg to 10 mg of elemental phosphorus per day."
- This claim combines the dilithium salt with the dosage range from Claim 16.
- Claim 23: "The method of claim 22 wherein said salt is administered in an amount of from 1 mg to 5 mg of elemental phosphorus per day."
- This claim combines the dilithium salt with the narrower dosage range from Claim 17.
The claims broadly cover the method of use and specify various alkali metal salts, with some claims further defining specific dosage ranges for elemental phosphorus.
What is the Chemical Structure of Etidronic Acid?
Etidronic acid, the foundational compound for patent 4,517,199, is a bisphosphonate with a specific chemical structure.
- Chemical Name: [1-hydroxyethane-1,1-diyl]bisphosphonic acid
- CAS Number: 2809-21-4
- Molecular Formula: C₂H₈O₇P₂
- Molecular Weight: 177.98 g/mol
- Structure:
OH
|
HO-P-C-P-OH
|| | ||
O CH3 O
The structure features a central carbon atom bonded to a hydroxyl group (-OH), a methyl group (-CH3), and two phosphonic acid groups (-PO(OH)₂). The presence of two phosphonate groups attached to the same carbon atom is characteristic of bisphosphonates.
The alkali metal salts of this acid involve the replacement of the acidic protons on the phosphonic acid groups with alkali metal cations (e.g., Na⁺, K⁺, Li⁺).
What is the Patent Landscape for Bisphosphonates and Osteoporosis Treatments?
The patent landscape surrounding bisphosphonates for osteoporosis is extensive, with patent 4,517,199 being an early but significant entry. Since its filing, numerous patents have been granted for new bisphosphonate compounds, improved formulations, and different therapeutic applications.
- Early Patents: Patent 4,517,199 represents foundational intellectual property in the field of bisphosphonate therapy for bone diseases. Other early patents likely covered the synthesis of bisphosphonate compounds themselves and their initial discovery for medicinal use.
- Second-Generation Bisphosphonates: The success of etidronate spurred research into more potent and orally bioavailable bisphosphonates. This led to patents for compounds like alendronate (e.g., U.S. Patent 4,921,842, also held by Merck & Co.), risedronate, and ibandronate. These patents often claimed novel chemical structures and improved therapeutic profiles.
- Third-Generation Bisphosphonates: Further innovations include nitrogen-containing bisphosphonates (e.g., zoledronic acid), which exhibit significantly higher potency. Patents in this era focused on these new chemical entities and their applications.
- Formulation and Delivery Patents: Beyond the API itself, patents have been filed for specific formulations designed to enhance efficacy, reduce side effects (such as gastrointestinal irritation), and improve patient compliance. This includes immediate-release, delayed-release, and intravenous formulations.
- Method of Use Patents: As with 4,517,199, patents continue to be filed for novel uses of existing bisphosphonates or for specific treatment regimens for various bone disorders, including Paget's disease, hypercalcemia of malignancy, and bone metastases.
- Patent Expiries and Generics: The expiry of foundational patents, such as 4,517,199, has been a critical driver for the entry of generic bisphosphonate products. This significantly reduces pricing and expands market access.
- Ongoing Innovation: Despite the maturity of the bisphosphonate field, research continues. Emerging areas might include combinations with other therapeutic agents, targeted delivery systems, and potentially patents on new modes of action or novel drug classes for bone health.
The patent landscape demonstrates a progression from fundamental compound discovery and basic methods of use to highly specific formulations and advanced chemical entities.
What is the Market Impact of Patent 4,517,199's Expiry?
The expiry of U.S. Patent 4,517,199 in 2002 had a profound and predictable impact on the market for osteoporosis treatments that utilized its protected method.
- Generic Competition: Upon expiry, the patent protection for the method of using etidronate salts (specifically etidronate disodium, the most commercially relevant form covered) to treat osteoporosis ceased. This opened the door for pharmaceutical companies to manufacture and sell generic versions of the drug.
- Price Reduction: The introduction of generic alternatives led to a substantial decrease in the price of etidronate-based osteoporosis treatments. This is a standard market dynamic following patent expiry for any successful drug.
- Increased Patient Access: Lower prices generally translate to increased patient access to treatment, particularly for individuals with limited insurance coverage or those seeking more affordable options.
- Market Share Shift: Generic etidronate products began to compete directly with any branded formulations of etidronate still available and with other osteoporosis treatments. This led to a redistribution of market share.
- Impact on R&D Investment: While the patent expiry facilitated generic access, it also meant that the exclusivity period for the original innovator for this specific method had ended. This would have influenced future R&D investment decisions by companies in the field, potentially shifting focus to developing novel compounds or improved delivery systems that could secure new patent protection.
- Regulatory Approvals: Generic manufacturers sought and obtained Abbreviated New Drug Applications (ANDAs) from the U.S. Food and Drug Administration (FDA) to market their versions. These approvals demonstrate bioequivalence to the reference listed drug.
The expiry of patent 4,517,199 marked a transition point from an exclusive market for this therapeutic method to a competitive generic market, benefiting consumers through cost savings.
What is the Status of Etidronate Disodium in the Market Today?
Etidronate disodium, the primary compound protected by patent 4,517,199, remains available in the market, primarily as a generic medication.
- Generic Availability: Etidronate disodium is widely available from multiple generic pharmaceutical manufacturers. It is prescribed for the treatment of Paget's disease of bone and heterotopic ossification. Its use in osteoporosis has largely been superseded by more potent bisphosphonates, but it can still be prescribed off-label or in specific patient populations.
- Therapeutic Regimens: When used, etidronate disodium is typically administered orally. Historically, treatment regimens involved cycles of drug administration followed by drug-free periods to minimize potential side effects, such as osteomalacia.
- Comparison to Newer Bisphosphonates: Newer generations of bisphosphonates, such as alendronate, risedronate, ibandronate, and zoledronic acid, generally offer higher potency, better oral bioavailability, and less complex dosing schedules (e.g., once-weekly or once-monthly oral dosing, or annual intravenous infusions). These newer drugs have captured a significant share of the osteoporosis market.
- Side Effect Profile: Etidronate disodium is associated with a risk of gastrointestinal side effects and, with long-term or high-dose use, can potentially impair bone mineralization, leading to osteomalacia. This side effect profile is one reason for its reduced role in osteoporosis management compared to newer agents.
- Regulatory Approvals: Etidronate disodium is approved by regulatory agencies like the FDA for specific indications, notably Paget's disease.
While no longer a first-line therapy for osteoporosis due to the availability of more potent alternatives, etidronate disodium continues to hold a place in the treatment of specific bone disorders and remains a cost-effective option.
Key Takeaways
- U.S. Patent 4,517,199, expired in 2002, protected the method of using alkali metal salts of etidronic acid to inhibit bone resorption, primarily for osteoporosis treatment.
- The patent's claims broadly covered various alkali metal salts and included some specific dosage ranges for elemental phosphorus.
- The patent's expiry facilitated the widespread availability of generic etidronate disodium, leading to significant price reductions and increased patient access.
- While etidronate disodium remains available and is used for conditions like Paget's disease, newer, more potent bisphosphonates have largely replaced it as the primary treatment for osteoporosis due to superior efficacy and dosing convenience.
- The patent landscape for bisphosphonates has evolved significantly since 4,517,199, with subsequent patents covering novel compounds, improved formulations, and alternative therapeutic applications.
Frequently Asked Questions
-
Can I still be treated with etidronate disodium?
Yes, etidronate disodium is still available and approved for specific conditions like Paget's disease. Its use for osteoporosis is less common due to the availability of more potent bisphosphonates.
-
What is the difference between etidronate and etidronate disodium?
Etidronate is the base acid. Etidronate disodium is a specific salt form of etidronic acid, where two sodium ions have replaced two acidic protons on the phosphonic acid groups. This salt form is typically used in pharmaceutical formulations due to its solubility and bioavailability.
-
Are there any patent protections remaining for etidronate disodium?
Patent 4,517,199, which protected the method of use described, has expired. Any remaining patents would likely relate to specific formulations, manufacturing processes, or novel uses not covered by the original patent.
-
Why did newer bisphosphonates become more popular than etidronate?
Newer bisphosphonates offer higher potency, allowing for lower doses and less frequent administration (e.g., weekly or monthly oral dosing), which improves patient adherence and reduces gastrointestinal side effects. They also generally have better oral bioavailability.
-
What other bone diseases can bisphosphonates treat?
Bisphosphonates are used to treat a range of bone diseases including Paget's disease, hypercalcemia of malignancy, bone metastases from various cancers, and osteogenesis imperfecta, in addition to osteoporosis.
Citations
[1] The Upjohn Company. (1985). United States Patent 4,517,199. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
